14 papers in the library · 534 citations · publishing 2019-2026
BJPsych Open May 13, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al.
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
Research Square February 23, 2026 Rotem Petranker, Norman A. S. Farb, Omer A. Syed et al.
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant effects and safety of repeated low doses of psilocybin in participants diagnosed with MDD. DESIGN This was a Phase II, randomized, double-blind, placebo-controlled clinical trial. SETTING The trial was conducted from July 2022 to December 2024 at two...
BJPsych Open February 16, 2026 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. 1 citation
BACKGROUND: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
November 16, 2025 Zeina Beidas, Anya Ragnhildstveit, Adam Blackman et al. preprint
Background: Major depressive disorder (MDD) is the leading cause of disability worldwide, affecting roughly 322 million people. Recently, doses of psilocybin have shown promise in treating mood disorders, sparking interest in other dosing practices. According to anecdotal reports and observational studies, microdosing psilocybin yields benefits to mental health; however, rigorously controlled...
Cureus May 1, 2024 Zach Hart, Thomas Anderson, Hanna Fanous et al. 2 citations
We report the case of a 64-year-old female with a history of hypothyroidism and isolated parotid sarcoidosis who presented with acute-onset chest pain and dyspnea. Echocardiogram demonstrated transiently reduced ejection fraction with apical hypokinesis, without evidence of obstructive coronary lesions on angiography, compatible with stress-induced cardiomyopathy. She received a ketamine...
Frontiers in Psychiatry February 5, 2024 Rotem Petranker, Thomas Anderson, Youval Aberman et al. 14 citations
Introduction The practice of taking small, sub-hallucinogenic doses of psychedelics, known as microdosing, has exploded in popularity over the last decade. Users claim benefits ranging from improved mood and enhanced creativity to an increased sense of meaning and connectedness in life. While research on microdosing is still lagging behind the shift in public opinion, several papers have been...
Journal of Humanistic Psychology February 14, 2022 Rotem Petranker, Juensung J. Kim, Thomas Anderson
The use of psychedelic substances in both humanistic and mainstream clinical research has been increasing in the last decade. In particular, the practice of microdosing—ingesting sub-hallucinogenic doses of psychedelics—has been increasing in popularity, but large-scale qualitative analyses are still uncommon. This study attempted to recognize emergent themes in qualitative reports regarding...
Journal of Psychopharmacology October 8, 2020 Rotem Petranker, Thomas Anderson, Larissa J. Maier et al. 57 citations
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containing mushrooms. Despite its surging popularity, little is known about the specific intentions to start microdosing and the effects of this practice. Aims: First, we aimed to replicate previous findings regarding the subjective benefits and challenges...
Frontiers in Psychology July 10, 2020 Rotem Petranker, Thomas Anderson, Norman A. S. Farb 66 citations
Psychedelics have a checkered past, alternately venerated as sacred medicines and vilified as narcotics with no medicinal or research value. After decades of international prohibition, a growing dissatisfaction with conventional mental health care and the pioneering work of the Multidisciplinary Association for Psychedelic Science (MAPS) and others has sparked a new wave of psychedelic...
May 26, 2020 Rotem Petranker, Juensung J. Kim, Thomas Anderson 4 citations preprint
Background: The use of psychedelic substances like LSD and magic mushrooms in research and to treat mental health conditions has been increasing in the last decade. In particular, the practice of microdosing – using sub-hallucinogenic amounts of psychedelics – has been increasing (Anderson et al., 2019), but large-scale systemic qualitative analyses are still scant.Aims: This study attempted to...
April 12, 2020 Rotem Petranker, Thomas Anderson, Larissa J. Maier et al. 14 citations preprint
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushrooms – is becoming increasingly popular. Despite its surging popularity, little is known about the effects of this practice. Aims: This research had three main aims. First, we attempted to replicate previous findings regarding the subjective benefits...
Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations
Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...
Harm Reduction Journal July 9, 2019 Thomas Anderson, Rotem Petranker, Adam Christopher et al. 130 citations
These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements...
Psychopharmacology January 2, 2019 Thomas Anderson, Rotem Petranker, Daniel Rosenbaum et al. 171 citations
RationaleMicrodosing psychedelics-the regular consumption of small amounts of psychedelic substances such as LSD or psilocybin-is a growing trend in popular culture. Recent studies on full-dose psychedelic psychotherapy reveal promising benefits for mental well-being, especially for depression and end-of-life anxiety. While full-dose therapies include perception-distorting properties,...